These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 343654

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Subcutaneous ancrod therapy in peripheral arterial disease: improvement in blood viscosity and nutritional blood flow.
    Lowe GD, Morrice JJ, Forbes CD, Prentice CR, Fulton AJ, Barbenel JC.
    Angiology; 1979 Sep; 30(9):594-9. PubMed ID: 484913
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Practical impact of hemorheology on the treatment of chronic peripheral ischemia.
    Dormandy JA.
    Angiology; 1981 Oct; 32(10):710-4. PubMed ID: 7325406
    [No Abstract] [Full Text] [Related]

  • 5. Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
    Wiles PG, Nelson SR, Hampton KK, Casali B, Boothby M, Prentice CR.
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):385-8. PubMed ID: 2133215
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fibrinogen/fibrin in atherogenesis.
    Smith EB, Thompson WD, Crosbie L, Stirk CM.
    Eur J Epidemiol; 1992 May; 8 Suppl 1():83-7. PubMed ID: 1387095
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation.
    Pollak VE, Glueck HI, Weiss MA, Lebron-Berges A, Miller MA.
    Am J Nephrol; 1982 May; 2(4):195-207. PubMed ID: 6816068
    [Abstract] [Full Text] [Related]

  • 14. [Pattern of blood viscosimetric values, fibrinogen, and various glycoproteins in patients with obliterating sclerotic peripheral vascular disease treated with 3GS].
    Sarno A, Bruno S, Romano A, Catania A, la Bruzzo S, Francavilla G, Caimi G.
    Clin Ter; 1980 Nov 15; 95(3):289-95. PubMed ID: 7214844
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
    Smith EB.
    Clin Haematol; 1986 May 15; 15(2):355-70. PubMed ID: 3524931
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Controlled evaluation of drugs in chronic vascular disease.
    Trübestein G.
    Angiology; 1981 Oct 15; 32(10):699-704. PubMed ID: 6173001
    [No Abstract] [Full Text] [Related]

  • 20. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S, Wadhwa NK, Kant KS, Pollak VE, Glas-Greenwalt P, Weiss MA, Hong CG.
    Q J Med; 1988 Nov 15; 69(259):879-905. PubMed ID: 3078212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.